Perceptive Advisors LLC Raises Stock Holdings in X4 Pharmaceuticals, Inc. $XFOR

Perceptive Advisors LLC raised its stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 6.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,737,648 shares of the company’s stock after buying an additional 423,196 shares during the quarter. Perceptive Advisors LLC owned about 0.07% of X4 Pharmaceuticals worth $27,826,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Bank of America Corp DE increased its position in shares of X4 Pharmaceuticals by 20.3% during the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after acquiring an additional 22,485 shares during the last quarter. Rhumbline Advisers raised its stake in shares of X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after acquiring an additional 9,690 shares during the period. Jane Street Group LLC lifted its holdings in shares of X4 Pharmaceuticals by 112.5% in the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after acquiring an additional 51,544 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of X4 Pharmaceuticals by 77.0% in the 3rd quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after acquiring an additional 178,593 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth approximately $47,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on XFOR shares. Leerink Partners initiated coverage on shares of X4 Pharmaceuticals in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 target price for the company. Wells Fargo & Company initiated coverage on X4 Pharmaceuticals in a research note on Friday, July 10th. They set an “overweight” rating and a $11.00 price target on the stock. Finally, Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, X4 Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $9.70.

X4 Pharmaceuticals Stock Performance

NASDAQ XFOR opened at $3.98 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 10.18 and a quick ratio of 9.98. The company has a market cap of $375.39 million, a P/E ratio of -0.88 and a beta of 0.35. The stock has a 50-day moving average of $4.01 and a two-hundred day moving average of $3.93. X4 Pharmaceuticals, Inc. has a 1-year low of $1.35 and a 1-year high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The business had revenue of $2.71 million for the quarter, compared to analysts’ expectations of $3.20 million. As a group, analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.77 EPS for the current year.

Insiders Place Their Bets

In related news, CFO David Kirske sold 8,543 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total transaction of $36,393.18. Following the sale, the chief financial officer directly owned 167,750 shares of the company’s stock, valued at $714,615. This represents a 4.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.13% of the stock is currently owned by insiders.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.